25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

MEGA-R (Mega Lifesciences Public Company Limited) Stock Analysis
Buy, Hold or Sell?

Let's analyze Mega Lifesciences Public Company Limited together

I guess you are interested in Mega Lifesciences Public Company Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Mega Lifesciences Public Company Limited’s Financial Insights
  • 📈 Technical Analysis (TA) – Mega Lifesciences Public Company Limited’s Price Targets

I'm going to help you getting a better view of Mega Lifesciences Public Company Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Mega Lifesciences Public Company Limited

I send you an email if I find something interesting about Mega Lifesciences Public Company Limited.

1. Quick Overview

1.1. Quick analysis of Mega Lifesciences Public Company Limited (30 sec.)










1.2. What can you expect buying and holding a share of Mega Lifesciences Public Company Limited? (30 sec.)

How much money do you get?

How much money do you get?
฿0.05
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
฿11.83
Expected worth in 1 year
฿12.27
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
฿2.03
Return On Investment
7.7%

For what price can you sell your share?

Current Price per Share
฿26.50
Expected price per share
฿25.25 - ฿30.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Mega Lifesciences Public Company Limited (5 min.)




Live pricePrice per Share (EOD)
฿26.50
Intrinsic Value Per Share
฿11.66 - ฿20.67
Total Value Per Share
฿23.50 - ฿32.50

2.2. Growth of Mega Lifesciences Public Company Limited (5 min.)




Is Mega Lifesciences Public Company Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$318.8m$288.1m$14.8m4.9%

How much money is Mega Lifesciences Public Company Limited making?

Current yearPrevious yearGrowGrow %
Making money$15.3m$15.5m-$252.2k-1.6%
Net Profit Margin13.5%12.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Mega Lifesciences Public Company Limited (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Mega Lifesciences Public Company Limited?

Welcome investor! Mega Lifesciences Public Company Limited's management wants to use your money to grow the business. In return you get a share of Mega Lifesciences Public Company Limited.

First you should know what it really means to hold a share of Mega Lifesciences Public Company Limited. And how you can make/lose money.

Speculation

The Price per Share of Mega Lifesciences Public Company Limited is ฿26.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mega Lifesciences Public Company Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mega Lifesciences Public Company Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ฿11.83. Based on the TTM, the Book Value Change Per Share is ฿0.11 per quarter. Based on the YOY, the Book Value Change Per Share is ฿0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ฿0.40 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mega Lifesciences Public Company Limited.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 ฿% of Price per Share฿% of Price per Share฿% of Price per Share฿% of Price per Share฿% of Price per Share฿% of Price per Share
Usd Eps0.020.1%0.020.1%0.020.1%0.020.1%0.020.1%0.010.0%
Usd Book Value Change Per Share0.020.1%0.000.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Dividend Per Share0.000.0%0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.020.1%0.020.1%0.020.1%0.020.1%0.020.1%0.010.0%
Usd Price Per Share0.96-1.10-1.23-1.12-0.84-0.42-
Price to Earnings Ratio15.06-16.31-17.21-16.03-12.81-6.41-
Price-to-Total Gains Ratio61.37-102.97-67.89-90.06-89.42-89.42-
Price to Book Ratio2.63-3.18-3.72-3.41-2.72-1.36-
Price-to-Total Gains Ratio61.37-102.97-67.89-90.06-89.42-89.42-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.81885
Number of shares1221
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.000.01
Usd Total Gains Per Share0.020.02
Gains per Quarter (1221 shares)19.1621.39
Gains per Year (1221 shares)76.6285.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1601667503576
21213214410170162
318149221151105248
424265298202141334
530281375252176420
636297452303211506
7423114529353246592
8483130606403281678
9543146683454316764
10604162760504351850

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%51.00.00.0100.0%
Book Value Change Per Share2.02.00.050.0%7.05.00.058.3%15.05.00.075.0%27.013.00.067.5%34.016.01.066.7%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%47.00.04.092.2%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%50.00.01.098.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Mega Lifesciences Public Company Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.5060.108+370%0.212+138%0.167+203%0.233+117%0.180+181%
Book Value Per Share--11.83511.248+5%10.697+11%10.657+11%9.759+21%7.811+52%
Current Ratio--2.8112.535+11%2.184+29%2.218+27%2.072+36%1.978+42%
Debt To Asset Ratio--0.2820.315-11%0.363-22%0.358-21%0.372-24%0.389-28%
Debt To Equity Ratio--0.3920.462-15%0.572-31%0.563-30%0.600-35%0.644-39%
Dividend Per Share--0.0000.400-100%0.413-100%0.405-100%0.334-100%0.248-100%
Enterprise Value--23044646576.14728145634135.587-18%32120616293.992-28%31808117818.249-28%30958399223.571-26%30958399223.571-26%
Eps--0.5160.569-9%0.578-11%0.589-12%0.561-8%0.428+20%
Ev To Sales Ratio--1.7961.889-5%2.052-12%2.069-13%2.067-13%2.067-13%
Free Cash Flow Per Share--0.1460.506-71%0.560-74%0.527-72%0.529-72%0.366-60%
Free Cash Flow To Equity Per Share--0.0990.130-24%0.079+26%0.109-9%0.141-30%0.104-5%
Gross Profit Margin--1.0000.256+291%-0.030+103%0.068+1366%-0.010+101%-0.348+135%
Intrinsic Value_10Y_max--20.665----------
Intrinsic Value_10Y_min--11.663----------
Intrinsic Value_1Y_max--2.105----------
Intrinsic Value_1Y_min--1.422----------
Intrinsic Value_3Y_max--6.299----------
Intrinsic Value_3Y_min--4.078----------
Intrinsic Value_5Y_max--10.461----------
Intrinsic Value_5Y_min--6.501----------
Market Cap23104555424.000-17%27090483576.14731010629135.587-13%34615528293.992-22%31708561083.395-15%23675981256.500+14%11837990628.250+129%
Net Profit Margin--0.1400.135+4%0.129+9%0.132+6%0.132+6%0.118+19%
Operating Margin---0.068-100%0.167-100%0.131-100%0.139-100%0.131-100%
Operating Ratio--1.2881.079+19%0.810+59%0.908+42%0.885+46%0.882+46%
Pb Ratio2.239-17%2.6253.178-17%3.718-29%3.414-23%2.716-3%1.358+93%
Pe Ratio12.841-17%15.05616.312-8%17.206-12%16.026-6%12.814+17%6.407+135%
Price Per Share26.500-17%31.07235.568-13%39.703-22%36.368-15%27.121+15%13.561+129%
Price To Free Cash Flow Ratio45.361-17%53.187-3.806+107%18.817+183%19.294+176%13.847+284%6.924+668%
Price To Total Gains Ratio52.340-17%61.369102.971-40%67.887-10%90.063-32%89.421-31%89.421-31%
Quick Ratio--0.8631.201-28%1.431-40%1.279-33%1.203-28%1.251-31%
Return On Assets--0.0310.035-9%0.034-9%0.035-11%0.036-13%0.033-4%
Return On Equity--0.0440.051-14%0.054-20%0.055-21%0.057-24%0.054-19%
Total Gains Per Share--0.5060.5080%0.625-19%0.572-12%0.567-11%0.428+18%
Usd Book Value--318834388.500303033588.525+5%288188270.625+11%287211781.700+11%263389472.535+21%210681640.718+51%
Usd Book Value Change Per Share--0.0160.003+370%0.007+138%0.005+203%0.007+117%0.006+181%
Usd Book Value Per Share--0.3660.348+5%0.331+11%0.329+11%0.302+21%0.241+52%
Usd Dividend Per Share--0.0000.012-100%0.013-100%0.013-100%0.010-100%0.008-100%
Usd Enterprise Value--712079579.203869700094.790-18%992527043.484-28%982870840.584-28%956614536.008-26%956614536.008-26%
Usd Eps--0.0160.018-9%0.018-11%0.018-12%0.017-8%0.013+20%
Usd Free Cash Flow--3934682.40013620426.450-71%15092788.275-74%14200179.975-72%14286849.840-72%9866454.975-60%
Usd Free Cash Flow Per Share--0.0050.016-71%0.017-74%0.016-72%0.016-72%0.011-60%
Usd Free Cash Flow To Equity Per Share--0.0030.004-24%0.002+26%0.003-9%0.004-30%0.003-5%
Usd Market Cap713930762.602-17%837095942.503958228440.290-13%1069619824.284-22%979794537.477-15%731587820.826+14%365793910.413+129%
Usd Price Per Share0.819-17%0.9601.099-13%1.227-22%1.124-15%0.838+15%0.419+129%
Usd Profit--13899932.40015331568.025-9%15583820.175-11%15662507.025-11%15011247.810-7%11492856.390+21%
Usd Revenue--99117188.400114477941.475-13%121170642.000-18%118706166.150-17%113661282.285-13%94757284.148+5%
Usd Total Gains Per Share--0.0160.0160%0.019-19%0.018-12%0.018-11%0.013+18%
 EOD+4 -4MRQTTM+13 -26YOY+15 -243Y+13 -265Y+14 -2510Y+19 -20

3.3 Fundamental Score

Let's check the fundamental score of Mega Lifesciences Public Company Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1512.841
Price to Book Ratio (EOD)Between0-12.239
Net Profit Margin (MRQ)Greater than00.140
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.863
Current Ratio (MRQ)Greater than12.811
Debt to Asset Ratio (MRQ)Less than10.282
Debt to Equity Ratio (MRQ)Less than10.392
Return on Equity (MRQ)Greater than0.150.044
Return on Assets (MRQ)Greater than0.050.031
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Mega Lifesciences Public Company Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose26.000
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Mega Lifesciences Public Company Limited

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provides various medicines for allergies; blood circulation and memory; bone and joint; liver and digestive; diabetics; eyes, heart, and skin care; pain, sleeping, well-being, herbal, and cough and colds; and vitamins, probiotics, medical and sports nutrition, as well as kids', men's, and women's care products. The company also offers prescription medicines in the areas of anti-allergic, anti-infective, central nervous system, cardiovascular system, dermatology, diabetes, gastroenterology, gynecology, nephrology, oncology, ophthalmology, orthopedic, pain, respiratory, rheumatology, and urology. In addition, it provides logistical and marketing services for the sale of goods manufactured by third parties, social enterprise, and wellness center, as well as involved in the software design, development, and other services business. The company was incorporated in 1982 and is headquartered in Bangkok, Thailand. Mega Lifesciences Public Company Limited operates as a subsidiary of Unistretch Limited.

Fundamental data was last updated by Penke on 2025-07-10 05:57:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Mega Lifesciences Public Company Limited earns for each ฿1 of revenue.

  • Above 10% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 14.0% means that ฿0.14 for each ฿1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 14.0%. The company is making a huge profit. +2
  • The TTM is 13.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.0%TTM13.5%+0.5%
TTM13.5%YOY12.9%+0.6%
TTM13.5%5Y13.2%+0.3%
5Y13.2%10Y11.8%+1.4%
4.3.1.2. Return on Assets

Shows how efficient Mega Lifesciences Public Company Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.1% Return on Assets means that Mega Lifesciences Public Company Limited generated ฿0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 3.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.1%TTM3.5%-0.3%
TTM3.5%YOY3.4%+0.0%
TTM3.5%5Y3.6%-0.1%
5Y3.6%10Y3.3%+0.3%
4.3.1.3. Return on Equity

Shows how efficient Mega Lifesciences Public Company Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.4% Return on Equity means Mega Lifesciences Public Company Limited generated ฿0.04 for each ฿1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 4.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 5.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.4%TTM5.1%-0.7%
TTM5.1%YOY5.4%-0.4%
TTM5.1%5Y5.7%-0.7%
5Y5.7%10Y5.4%+0.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Mega Lifesciences Public Company Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Mega Lifesciences Public Company Limited is operating .

  • Measures how much profit Mega Lifesciences Public Company Limited makes for each ฿1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ฿0.00  for each ฿1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM6.8%-6.8%
TTM6.8%YOY16.7%-9.9%
TTM6.8%5Y13.9%-7.1%
5Y13.9%10Y13.1%+0.7%
4.3.2.2. Operating Ratio

Measures how efficient Mega Lifesciences Public Company Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.29 means that the operating costs are ฿1.29 for each ฿1 in net sales.

Let's take a look of the Operating Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 1.288. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.079. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.288TTM1.079+0.209
TTM1.079YOY0.810+0.270
TTM1.0795Y0.885+0.194
5Y0.88510Y0.882+0.003
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Mega Lifesciences Public Company Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.81 means the company has ฿2.81 in assets for each ฿1 in short-term debts.

Let's take a look of the Current Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 2.811. The company is able to pay all its short-term debts. +1
  • The TTM is 2.535. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.811TTM2.535+0.276
TTM2.535YOY2.184+0.351
TTM2.5355Y2.072+0.463
5Y2.07210Y1.978+0.093
4.4.3.2. Quick Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.86 means the company can pay off ฿0.86 for each ฿1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.863. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.201. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.863TTM1.201-0.338
TTM1.201YOY1.431-0.230
TTM1.2015Y1.203-0.002
5Y1.20310Y1.251-0.048
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Mega Lifesciences Public Company Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Mega Lifesciences Public Company Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mega Lifesciences Public Company Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.28 means that Mega Lifesciences Public Company Limited assets are financed with 28.2% credit (debt) and the remaining percentage (100% - 28.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.282. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.315. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.282TTM0.315-0.033
TTM0.315YOY0.363-0.048
TTM0.3155Y0.372-0.057
5Y0.37210Y0.389-0.017
4.5.4.2. Debt to Equity Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 39.2% means that company has ฿0.39 debt for each ฿1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.392. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.462. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.392TTM0.462-0.070
TTM0.462YOY0.572-0.110
TTM0.4625Y0.600-0.138
5Y0.60010Y0.644-0.044
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ฿1 in earnings Mega Lifesciences Public Company Limited generates.

  • Above 15 is considered overpriced but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 15.06 means the investor is paying ฿15.06 for every ฿1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 12.841. Based on the earnings, the company is underpriced. +1
  • The MRQ is 15.056. Based on the earnings, the company is fair priced.
  • The TTM is 16.312. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD12.841MRQ15.056-2.215
MRQ15.056TTM16.312-1.257
TTM16.312YOY17.206-0.893
TTM16.3125Y12.814+3.498
5Y12.81410Y6.407+6.407
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 45.361. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 53.187. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is -3.806. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD45.361MRQ53.187-7.826
MRQ53.187TTM-3.806+56.993
TTM-3.806YOY18.817-22.623
TTM-3.8065Y13.847-17.653
5Y13.84710Y6.924+6.924
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Mega Lifesciences Public Company Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.63 means the investor is paying ฿2.63 for each ฿1 in book value.

Let's take a look of the Price to Book Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 2.239. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.625. Based on the equity, the company is underpriced. +1
  • The TTM is 3.178. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.239MRQ2.625-0.386
MRQ2.625TTM3.178-0.552
TTM3.178YOY3.718-0.541
TTM3.1785Y2.716+0.462
5Y2.71610Y1.358+1.358
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in THB. All numbers in thousands.

Summary
Total Assets14,364,102
Total Liabilities4,045,837
Total Stockholder Equity10,318,150
 As reported
Total Liabilities 4,045,837
Total Stockholder Equity+ 10,318,150
Total Assets = 14,364,102

Assets

Total Assets14,364,102
Total Current Assets10,149,643
Long-term Assets4,214,459
Total Current Assets
Cash And Cash Equivalents 3,559,030
Short-term Investments 350,140
Net Receivables 2,764,485
Inventory 3,004,293
Total Current Assets  (as reported)10,149,643
Total Current Assets  (calculated)9,677,948
+/- 471,695
Long-term Assets
Property Plant Equipment 2,220,052
Goodwill 444,234
Long Term Investments 40,254
Intangible Assets 868,922
Long-term Assets Other 289,376
Long-term Assets  (as reported)4,214,459
Long-term Assets  (calculated)3,862,838
+/- 351,621

Liabilities & Shareholders' Equity

Total Current Liabilities3,610,552
Long-term Liabilities435,285
Total Stockholder Equity10,318,150
Total Current Liabilities
Short Long Term Debt 268,398
Accounts payable 1,556,353
Total Current Liabilities  (as reported)3,610,552
Total Current Liabilities  (calculated)1,824,751
+/- 1,785,801
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt208,718
Long-term Liabilities  (as reported)435,285
Long-term Liabilities  (calculated)208,718
+/- 226,567
Total Stockholder Equity
Retained Earnings 8,205,363
Total Stockholder Equity (as reported)10,318,150
Total Stockholder Equity (calculated)8,205,363
+/- 2,112,787
Other
Capital Stock435,935
Common Stock Shares Outstanding 871,870
Net Invested Capital 10,586,548
Net Working Capital 6,539,091
Property Plant and Equipment Gross 2,220,052



6.2. Balance Sheets Structured

Currency in THB. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-30
> Total Assets 
0
0
4,135,256
4,491,874
4,883,636
5,147,679
6,535,853
6,874,311
6,547,117
6,524,934
6,722,439
6,736,356
7,009,635
7,255,245
7,612,547
7,338,548
7,328,173
7,471,991
7,940,973
7,815,990
8,222,537
8,326,657
8,719,842
8,476,532
8,768,418
8,602,250
9,632,593
9,972,396
10,092,140
10,191,281
10,532,705
11,189,919
11,325,857
11,693,640
11,589,714
11,430,970
11,733,793
12,548,005
13,271,700
13,639,790
14,470,549
14,074,084
14,646,435
14,701,028
14,697,428
14,738,993
14,519,378
14,578,492
15,189,665
13,532,761
14,210,134
14,364,102
14,364,10214,210,13413,532,76115,189,66514,578,49214,519,37814,738,99314,697,42814,701,02814,646,43514,074,08414,470,54913,639,79013,271,70012,548,00511,733,79311,430,97011,589,71411,693,64011,325,85711,189,91910,532,70510,191,28110,092,1409,972,3969,632,5938,602,2508,768,4188,476,5328,719,8428,326,6578,222,5377,815,9907,940,9737,471,9917,328,1737,338,5487,612,5477,255,2457,009,6356,736,3566,722,4396,524,9346,547,1176,874,3116,535,8535,147,6794,883,6364,491,8744,135,25600
   > Total Current Assets 
0
0
3,170,393
3,352,824
3,705,968
3,891,562
5,225,293
5,497,301
5,137,908
5,138,381
4,840,837
5,356,747
5,606,577
5,825,633
6,169,244
5,874,442
5,716,991
5,697,318
5,688,893
5,601,599
6,048,110
5,821,096
6,470,143
6,187,528
6,352,813
6,268,947
6,468,614
6,900,413
6,956,848
6,974,404
7,245,836
7,230,612
7,318,963
7,603,887
7,619,823
7,380,400
7,720,951
8,568,085
9,300,879
9,620,392
10,340,694
9,893,184
10,589,994
10,645,467
10,558,440
10,555,119
9,990,008
10,089,402
10,699,648
9,571,946
10,226,694
10,149,643
10,149,64310,226,6949,571,94610,699,64810,089,4029,990,00810,555,11910,558,44010,645,46710,589,9949,893,18410,340,6949,620,3929,300,8798,568,0857,720,9517,380,4007,619,8237,603,8877,318,9637,230,6127,245,8366,974,4046,956,8486,900,4136,468,6146,268,9476,352,8136,187,5286,470,1435,821,0966,048,1105,601,5995,688,8935,697,3185,716,9915,874,4426,169,2445,825,6335,606,5775,356,7474,840,8375,138,3815,137,9085,497,3015,225,2933,891,5623,705,9683,352,8243,170,39300
       Cash And Cash Equivalents 
0
0
353,786
359,562
331,227
352,074
1,540,309
1,584,230
1,300,262
1,237,433
340,634
332,548
326,911
288,727
515,679
1,016,022
1,032,053
809,240
565,856
518,364
692,124
476,525
477,671
712,145
468,966
442,110
559,532
610,485
846,762
1,078,264
1,247,922
998,011
1,038,747
979,423
1,006,451
1,490,461
1,484,882
1,631,935
2,197,692
2,240,723
2,119,941
1,622,876
2,453,465
2,655,096
2,413,732
2,114,248
2,366,162
2,978,024
3,687,148
2,909,252
3,462,731
3,559,030
3,559,0303,462,7312,909,2523,687,1482,978,0242,366,1622,114,2482,413,7322,655,0962,453,4651,622,8762,119,9412,240,7232,197,6921,631,9351,484,8821,490,4611,006,451979,4231,038,747998,0111,247,9221,078,264846,762610,485559,532442,110468,966712,145477,671476,525692,124518,364565,856809,2401,032,0531,016,022515,679288,727326,911332,548340,6341,237,4331,300,2621,584,2301,540,309352,074331,227359,562353,78600
       Short-term Investments 
0
0
5,168
0
0
0
21,492
0
0
0
433,832
939,314
939,314
951,111
951,111
444,573
444,573
650,938
651,656
650,938
673,834
477,559
696,754
731,076
708,423
666,964
367,330
574,473
574,473
236,922
207,142
211,091
211,091
211,091
211,091
371,267
333,660
333,660
333,660
335,412
335,412
335,412
335,412
336,957
336,956
336,957
355,522
347,117
6,482
6,151
350,298
350,140
350,140350,2986,1516,482347,117355,522336,957336,956336,957335,412335,412335,412335,412333,660333,660333,660371,267211,091211,091211,091211,091207,142236,922574,473574,473367,330666,964708,423731,076696,754477,559673,834650,938651,656650,938444,573444,573951,111951,111939,314939,314433,83200021,4920005,16800
       Net Receivables 
0
0
1,208,902
1,135,975
1,681,743
1,574,030
1,747,374
1,576,276
1,624,309
1,906,847
2,023,762
2,115,782
2,322,481
2,176,077
2,306,436
2,083,426
1,971,190
2,092,116
2,287,349
2,149,426
2,292,921
2,420,078
2,615,878
2,238,139
2,598,023
2,485,083
2,612,093
2,694,991
2,567,349
2,651,095
2,538,900
2,938,159
2,748,106
2,703,804
2,506,758
2,187,762
2,534,839
2,962,725
2,721,433
3,186,344
3,882,582
3,780,938
3,251,607
3,367,419
3,628,055
3,827,721
3,472,034
3,301,465
3,417,334
3,264,628
2,975,207
2,764,485
2,764,4852,975,2073,264,6283,417,3343,301,4653,472,0343,827,7213,628,0553,367,4193,251,6073,780,9383,882,5823,186,3442,721,4332,962,7252,534,8392,187,7622,506,7582,703,8042,748,1062,938,1592,538,9002,651,0952,567,3492,694,9912,612,0932,485,0832,598,0232,238,1392,615,8782,420,0782,292,9212,149,4262,287,3492,092,1161,971,1902,083,4262,306,4362,176,0772,322,4812,115,7822,023,7621,906,8471,624,3091,576,2761,747,3741,574,0301,681,7431,135,9751,208,90200
       Other Current Assets 
0
0
358,546
245,242
73,747
242,337
231,193
421,684
349,370
293,196
402,549
354,344
330,158
375,182
326,896
395,550
341,432
170,447
326,302
206,691
227,780
177,378
539,206
235,186
200,457
197,524
410,190
322,823
237,778
217,121
367,551
290,123
177,230
165,152
71,025
286,278
275,046
215,372
380,405
130,315
138,445
170,221
575,241
244,256
291,024
338,965
577,101
10,017
280,726
274,076
0
0
00274,076280,72610,017577,101338,965291,024244,256575,241170,221138,445130,315380,405215,372275,046286,27871,025165,152177,230290,123367,551217,121237,778322,823410,190197,524200,457235,186539,206177,378227,780206,691326,302170,447341,432395,550326,896375,182330,158354,344402,549293,196349,370421,684231,193242,33773,747245,242358,54600
   > Long-term Assets 
0
0
964,862
1,139,050
1,177,668
1,256,117
1,310,560
1,377,010
1,409,209
1,386,553
1,881,602
1,379,609
1,403,058
1,429,612
1,443,303
1,464,106
1,611,182
1,774,673
2,252,080
2,214,391
2,174,427
2,505,561
2,249,699
2,289,004
2,415,605
2,333,303
3,163,979
3,071,983
3,135,292
3,216,877
3,286,869
3,959,307
4,006,894
4,089,753
3,969,891
4,050,570
4,012,842
3,979,920
3,970,821
4,019,398
4,129,855
4,180,900
4,056,441
4,055,561
4,138,988
4,183,874
4,529,370
4,489,090
4,490,017
3,960,815
3,983,440
4,214,459
4,214,4593,983,4403,960,8154,490,0174,489,0904,529,3704,183,8744,138,9884,055,5614,056,4414,180,9004,129,8554,019,3983,970,8213,979,9204,012,8424,050,5703,969,8914,089,7534,006,8943,959,3073,286,8693,216,8773,135,2923,071,9833,163,9792,333,3032,415,6052,289,0042,249,6992,505,5612,174,4272,214,3912,252,0801,774,6731,611,1821,464,1061,443,3031,429,6121,403,0581,379,6091,881,6021,386,5531,409,2091,377,0101,310,5601,256,1171,177,6681,139,050964,86200
       Property Plant Equipment 
0
0
731,847
810,732
853,159
921,275
969,507
1,002,486
1,012,916
987,506
980,141
978,247
991,238
1,013,573
1,031,495
1,019,629
1,192,593
1,169,257
1,164,284
1,142,178
1,117,349
1,193,308
1,183,037
1,233,595
1,274,290
1,260,438
1,425,989
1,544,455
1,635,074
1,693,559
1,770,592
2,222,409
2,194,696
2,307,840
2,213,797
2,236,784
2,176,368
2,081,560
2,102,739
2,174,003
2,194,061
2,171,903
2,150,568
2,129,594
2,198,333
2,206,326
2,225,287
2,291,824
2,300,103
2,203,059
2,212,922
2,220,052
2,220,0522,212,9222,203,0592,300,1032,291,8242,225,2872,206,3262,198,3332,129,5942,150,5682,171,9032,194,0612,174,0032,102,7392,081,5602,176,3682,236,7842,213,7972,307,8402,194,6962,222,4091,770,5921,693,5591,635,0741,544,4551,425,9891,260,4381,274,2901,233,5951,183,0371,193,3081,117,3491,142,1781,164,2841,169,2571,192,5931,019,6291,031,4951,013,573991,238978,247980,141987,5061,012,9161,002,486969,507921,275853,159810,732731,84700
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
153,581
149,879
215,654
215,221
219,472
220,498
223,610
213,130
212,585
212,443
202,332
199,032
199,421
427,829
435,815
442,296
437,318
443,866
453,717
481,095
476,253
480,300
488,673
505,473
465,883
470,095
478,602
482,993
456,242
473,978
471,307
458,712
448,999
444,234
444,234448,999458,712471,307473,978456,242482,993478,602470,095465,883505,473488,673480,300476,253481,095453,717443,866437,318442,296435,815427,829199,421199,032202,332212,443212,585213,130223,610220,498219,472215,221215,654149,879153,581000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
248,582
245,226
240,568
258,008
240,521
205,213
194,469
202,617
0
218,530
214,789
213,941
226,777
243,661
222,875
220,616
228,566
233,646
221,146
235,035
237,440
38,407
40,390
40,254
40,25440,39038,407237,440235,035221,146233,646228,566220,616222,875243,661226,777213,941214,789218,5300202,617194,469205,213240,521258,008240,568245,226248,5820000000000000000000000000000
       Intangible Assets 
0
0
194,325
15,652
206,215
209,504
213,016
217,469
221,322
223,653
230,211
232,417
234,704
234,627
232,700
231,414
239,059
384,127
719,087
702,249
643,059
674,726
674,465
669,552
680,659
645,221
929,462
926,921
909,426
902,814
903,905
864,888
861,304
878,093
874,999
883,104
863,304
885,722
876,886
868,475
874,821
882,360
863,309
862,220
860,893
875,729
862,228
875,039
876,057
874,440
869,719
868,922
868,922869,719874,440876,057875,039862,228875,729860,893862,220863,309882,360874,821868,475876,886885,722863,304883,104874,999878,093861,304864,888903,905902,814909,426926,921929,462645,221680,659669,552674,465674,726643,059702,249719,087384,127239,059231,414232,700234,627234,704232,417230,211223,653221,322217,469213,016209,504206,21515,652194,32500
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
255,279
287,714
284,120
186,173
274,558
256,311
249,308
284,199
0
313,013
300,154
282,679
345,523
377,503
353,806
0
372,594
0
0
0
0
0
0
0
0000000372,5940353,806377,503345,523282,679300,154313,0130284,199249,308256,311274,558186,173284,120287,714255,2790000000000000000000000000000
> Total Liabilities 
0
0
2,509,015
2,724,380
3,144,588
3,293,727
2,843,280
3,120,408
2,818,268
2,799,293
2,744,177
2,699,283
2,992,226
3,203,284
3,277,879
2,876,442
2,870,863
3,075,611
3,261,163
2,987,757
3,313,800
3,447,798
3,475,446
3,020,429
3,323,471
3,307,660
3,908,251
3,951,451
4,272,286
4,395,715
4,357,609
4,932,811
4,819,135
5,037,854
4,610,790
4,109,739
4,395,322
5,053,997
5,246,579
5,019,986
5,974,087
5,544,491
5,869,706
5,498,830
5,601,995
5,773,532
5,217,199
4,635,640
5,394,895
4,294,982
4,333,299
4,045,837
4,045,8374,333,2994,294,9825,394,8954,635,6405,217,1995,773,5325,601,9955,498,8305,869,7065,544,4915,974,0875,019,9865,246,5795,053,9974,395,3224,109,7394,610,7905,037,8544,819,1354,932,8114,357,6094,395,7154,272,2863,951,4513,908,2513,307,6603,323,4713,020,4293,475,4463,447,7983,313,8002,987,7573,261,1633,075,6112,870,8632,876,4423,277,8793,203,2842,992,2262,699,2832,744,1772,799,2932,818,2683,120,4082,843,2803,293,7273,144,5882,724,3802,509,01500
   > Total Current Liabilities 
0
0
2,091,435
2,324,947
2,693,182
2,820,360
2,547,407
2,840,884
2,554,205
2,552,224
2,511,426
2,484,835
2,788,011
2,987,143
3,095,241
2,721,683
2,735,763
2,966,860
3,152,888
2,879,212
3,205,633
3,338,753
3,366,226
2,906,146
3,202,914
3,178,282
3,774,942
3,816,270
4,097,134
4,213,590
4,158,166
4,584,518
4,455,549
4,667,099
4,261,663
3,706,119
3,992,325
4,659,291
4,853,355
4,624,525
5,590,429
5,157,354
5,538,040
5,170,875
5,251,583
5,422,989
4,436,565
3,991,076
4,751,162
3,885,959
3,914,314
3,610,552
3,610,5523,914,3143,885,9594,751,1623,991,0764,436,5655,422,9895,251,5835,170,8755,538,0405,157,3545,590,4294,624,5254,853,3554,659,2913,992,3253,706,1194,261,6634,667,0994,455,5494,584,5184,158,1664,213,5904,097,1343,816,2703,774,9423,178,2823,202,9142,906,1463,366,2263,338,7533,205,6332,879,2123,152,8882,966,8602,735,7632,721,6833,095,2412,987,1432,788,0112,484,8352,511,4262,552,2242,554,2052,840,8842,547,4072,820,3602,693,1822,324,9472,091,43500
       Short-term Debt 
0
0
851,466
942,590
1,208,997
1,221,678
784,691
834,981
820,757
816,611
429,778
439,892
595,779
627,029
634,234
427,670
633,677
618,200
663,093
441,938
734,090
674,993
512,169
311,530
618,166
712,079
957,591
947,462
1,227,627
1,167,193
889,624
847,280
1,128,727
840,855
536,159
312,805
260,592
214,125
224,386
171,587
273,701
342,156
312,143
299,824
329,365
128,449
119,778
159,945
244,142
233,378
0
0
00233,378244,142159,945119,778128,449329,365299,824312,143342,156273,701171,587224,386214,125260,592312,805536,159840,8551,128,727847,280889,6241,167,1931,227,627947,462957,591712,079618,166311,530512,169674,993734,090441,938663,093618,200633,677427,670634,234627,029595,779439,892429,778816,611820,757834,981784,6911,221,6781,208,997942,590851,46600
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,226,396
1,165,943
888,306
795,949
1,081,193
796,069
499,491
259,246
0
156,189
168,176
113,554
187,522
257,789
229,180
224,244
274,991
80,975
76,000
93,011
176,747
168,747
287,584
268,398
268,398287,584168,747176,74793,01176,00080,975274,991224,244229,180257,789187,522113,554168,176156,1890259,246499,491796,0691,081,193795,949888,3061,165,9431,226,3960000000000000000000000000000
       Accounts payable 
0
0
768,912
883,141
896,238
1,076,285
1,167,869
1,452,560
1,255,448
1,204,377
1,305,884
1,410,209
1,354,696
1,513,359
1,602,895
1,313,020
1,346,849
1,519,833
1,518,603
1,434,242
1,441,047
1,559,850
1,598,159
1,513,623
1,575,404
1,564,114
1,690,770
1,713,519
1,703,818
1,816,502
2,019,591
1,973,590
1,943,201
2,448,183
2,047,757
1,794,744
2,235,361
2,665,863
2,526,618
2,269,949
2,744,970
2,731,246
2,793,380
2,442,944
2,669,993
2,514,255
1,924,814
1,845,667
2,359,482
1,841,308
1,685,010
1,556,353
1,556,3531,685,0101,841,3082,359,4821,845,6671,924,8142,514,2552,669,9932,442,9442,793,3802,731,2462,744,9702,269,9492,526,6182,665,8632,235,3611,794,7442,047,7572,448,1831,943,2011,973,5902,019,5911,816,5021,703,8181,713,5191,690,7701,564,1141,575,4041,513,6231,598,1591,559,8501,441,0471,434,2421,518,6031,519,8331,346,8491,313,0201,602,8951,513,3591,354,6961,410,2091,305,8841,204,3771,255,4481,452,5601,167,8691,076,285896,238883,141768,91200
       Other Current Liabilities 
0
0
238,743
499,216
537,598
501,412
607,056
488,412
432,502
520,359
1,002,279
561,924
769,513
811,127
1,049,068
878,081
693,809
793,498
1,221,840
914,542
986,232
1,034,199
1,692,012
905,897
930,630
876,645
1,404,109
1,070,670
1,115,504
1,179,314
1,027,271
1,590,665
1,269,742
1,274,687
1,075,694
1,365,991
1,333,043
1,635,969
1,492,643
1,909,128
2,357,437
1,917,598
1,938,628
2,186,230
2,126,199
2,725,606
2,199,606
1,796,588
1,977,268
1,783,045
0
0
001,783,0451,977,2681,796,5882,199,6062,725,6062,126,1992,186,2301,938,6281,917,5982,357,4371,909,1281,492,6431,635,9691,333,0431,365,9911,075,6941,274,6871,269,7421,590,6651,027,2711,179,3141,115,5041,070,6701,404,109876,645930,630905,8971,692,0121,034,199986,232914,5421,221,840793,498693,809878,0811,049,068811,127769,513561,9241,002,279520,359432,502488,412607,056501,412537,598499,216238,74300
   > Long-term Liabilities 
0
0
417,580
399,433
451,406
473,367
295,873
279,524
264,063
247,069
232,751
214,448
204,215
216,141
182,638
154,759
135,100
108,751
108,275
108,545
108,167
109,045
109,220
114,283
120,557
129,378
133,309
135,181
175,152
182,125
199,443
348,293
363,586
370,755
349,127
403,620
402,997
394,706
393,224
395,461
383,658
387,137
331,666
327,955
350,412
350,543
780,634
644,564
643,733
409,023
418,985
435,285
435,285418,985409,023643,733644,564780,634350,543350,412327,955331,666387,137383,658395,461393,224394,706402,997403,620349,127370,755363,586348,293199,443182,125175,152135,181133,309129,378120,557114,283109,220109,045108,167108,545108,275108,751135,100154,759182,638216,141204,215214,448232,751247,069264,063279,524295,873473,367451,406399,433417,58000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
173,626
180,953
198,591
228,665
238,735
247,955
237,819
247,088
0
258,185
261,281
269,360
278,194
289,162
222,938
0
231,962
0
0
0
0
0
0
0
0000000231,9620222,938289,162278,194269,360261,281258,1850247,088237,819247,955238,735228,665198,591180,953173,6260000000000000000000000000000
> Total Stockholder Equity
0
0
1,602,859
1,746,596
1,718,548
1,853,928
3,692,561
3,753,926
3,728,901
3,725,658
3,978,280
4,037,106
4,017,427
4,051,961
4,334,690
4,462,024
4,457,267
4,396,374
4,679,804
4,828,204
4,908,718
4,878,825
5,244,361
5,456,064
5,444,903
5,294,516
5,724,254
6,020,800
5,819,748
5,795,471
6,174,998
6,235,502
6,482,492
6,633,448
6,957,637
7,299,783
7,317,098
7,468,950
8,002,820
8,599,557
8,496,324
8,529,498
8,776,657
9,202,080
9,095,325
8,965,475
9,302,162
9,942,841
9,794,732
9,237,644
9,876,759
10,318,150
10,318,1509,876,7599,237,6449,794,7329,942,8419,302,1628,965,4759,095,3259,202,0808,776,6578,529,4988,496,3248,599,5578,002,8207,468,9507,317,0987,299,7836,957,6376,633,4486,482,4926,235,5026,174,9985,795,4715,819,7486,020,8005,724,2545,294,5165,444,9035,456,0645,244,3614,878,8254,908,7184,828,2044,679,8044,396,3744,457,2674,462,0244,334,6904,051,9614,017,4274,037,1063,978,2803,725,6583,728,9013,753,9263,692,5611,853,9281,718,5481,746,5961,602,85900
   Common Stock
0
0
67,056
67,056
67,056
367,731
432,624
432,624
432,624
432,624
432,625
432,625
432,625
432,625
432,625
432,625
432,625
432,625
432,625
432,625
432,625
432,625
432,625
432,625
432,625
432,625
433,385
435,333
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
0
0
00435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,333433,385432,625432,625432,625432,625432,625432,625432,625432,625432,625432,625432,625432,625432,625432,625432,625432,625432,624432,624432,624432,624367,73167,05667,05667,05600
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
13,114
-198,987
13,114
36,176
49,088
49,088
52,088
54,288
59,088
60,688
64,088
67,088
72,488
73,058
74,148
74,148
74,148
74,148
74,148
74,148
74,148
74,148
74,148
74,148
74,148
74,148
74,148
74,148
74,048
74,048
74,048
74,048
74,048
74,048
74,048
72,557
74,088
74,088
74,088
88,210
88,210
88,210
88,210
88,210
-574,026
-410,995
-374,410
88,210
0
0
0088,210-374,410-410,995-574,02688,21088,21088,21088,21088,21074,08874,08874,08872,55774,04874,04874,04874,04874,04874,04874,04874,14874,14874,14874,14874,14874,14874,14874,14874,14874,14874,14874,14874,14874,14873,05872,48867,08864,08860,68859,08854,28852,08849,08849,08836,17613,114-198,98713,11400
   Capital Surplus 0000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
-137,055
0
-286,886
-172,405
2,187,192
2,187,192
2,190,192
2,192,392
2,197,192
2,198,792
2,202,192
2,205,192
2,210,592
2,211,162
2,212,252
2,168,920
2,138,104
2,138,104
2,138,104
2,138,104
2,138,104
2,138,104
2,138,104
2,138,104
2,176,628
2,275,430
2,304,524
2,304,524
2,304,523
2,304,523
2,378,571
2,378,571
2,378,571
2,304,523
2,304,523
2,304,523
2,378,611
2,378,611
2,304,523
2,304,523
2,304,523
2,304,523
2,304,523
2,378,611
2,304,523
2,304,523
2,304,523
1,599,771
0
0
001,599,7712,304,5232,304,5232,304,5232,378,6112,304,5232,304,5232,304,5232,304,5232,304,5232,378,6112,378,6112,304,5232,304,5232,304,5232,378,5712,378,5712,378,5712,304,5232,304,5232,304,5242,304,5242,275,4302,176,6282,138,1042,138,1042,138,1042,138,1042,138,1042,138,1042,138,1042,138,1042,168,9202,212,2522,211,1622,210,5922,205,1922,202,1922,198,7922,197,1922,192,3922,190,1922,187,1922,187,192-172,405-286,8860-137,05500



6.3. Balance Sheets

Currency in THB. All numbers in thousands.




6.4. Cash Flows

Currency in THB. All numbers in thousands.




6.5. Income Statements

Currency in THB. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in THB. All numbers in thousands.

Gross Profit (+$)
totalRevenue15,344,136
Cost of Revenue-7,589,703
Gross Profit7,754,4337,754,433
 
Operating Income (+$)
Gross Profit7,754,433
Operating Expense-11,974,250
Operating Income3,369,886-4,219,817
 
Operating Expense (+$)
Research Development44,047
Selling General Administrative4,218,075
Selling And Marketing Expenses0
Operating Expense11,974,2504,262,122
 
Net Interest Income (+$)
Interest Income0
Interest Expense-38,494
Other Finance Cost-0
Net Interest Income-38,494
 
Pretax Income (+$)
Operating Income3,369,886
Net Interest Income-38,494
Other Non-Operating Income Expenses0
Income Before Tax (EBT)2,352,1834,349,095
EBIT - interestExpense = -38,494
2,012,481
2,050,975
Interest Expense38,494
Earnings Before Interest and Taxes (EBIT)02,390,677
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax2,352,183
Tax Provision-339,628
Net Income From Continuing Ops2,012,5552,012,555
Net Income2,012,481
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-979,20938,494
 

Technical Analysis of Mega Lifesciences Public Company Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Mega Lifesciences Public Company Limited. The general trend of Mega Lifesciences Public Company Limited is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Mega Lifesciences Public Company Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Mega Lifesciences Public Company Limited Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Mega Lifesciences Public Company Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 30.00 < 30.00 < 30.00.

The bearish price targets are: 25.25.

Know someone who trades $MEGA-R? Share this with them.👇

Mega Lifesciences Public Company Limited Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Mega Lifesciences Public Company Limited. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Mega Lifesciences Public Company Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Moving Average Convergence/Divergence (MACD) ChartMega Lifesciences Public Company Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Mega Lifesciences Public Company Limited. The current adx is .

Mega Lifesciences Public Company Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Relative Strength Index (RSI) ChartMega Lifesciences Public Company Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Stochastic Oscillator ChartMega Lifesciences Public Company Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Commodity Channel Index (CCI) ChartMega Lifesciences Public Company Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Chande Momentum Oscillator (CMO) ChartMega Lifesciences Public Company Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Williams %R ChartMega Lifesciences Public Company Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Average True Range (ATR) ChartMega Lifesciences Public Company Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily On-Balance Volume (OBV) ChartMega Lifesciences Public Company Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Mega Lifesciences Public Company Limited.

Mega Lifesciences Public Company Limited Daily Money Flow Index (MFI) ChartMega Lifesciences Public Company Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Mega Lifesciences Public Company Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Mega Lifesciences Public Company Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Mega Lifesciences Public Company Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose26.000
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Mega Lifesciences Public Company Limited with someone you think should read this too:
  • Are you bullish or bearish on Mega Lifesciences Public Company Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Mega Lifesciences Public Company Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Mega Lifesciences Public Company Limited

I send you an email if I find something interesting about Mega Lifesciences Public Company Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Mega Lifesciences Public Company Limited.

Receive notifications about Mega Lifesciences Public Company Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.